Tien Nguyen, MD
Dermatology · Fountain Valley, CANPI 1396741351
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $978,659 of the $1,224,105 with a category attached, or 79.9%. It is spread thinly across 55 manufacturers, the largest accounting for just 16.8%. 2025 is the largest year on record at $296,700, 2.1 times the $138,949 reported in 2019. Among dermatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,431 payments — averaging $503.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$205K
- Sanofi$103K
- UCB, Inc.$98K
- LEO Pharma Inc.$93K
- Amgen$80K
- Pfizer$73K
- plus $571K from 49 others
Across 379 payments — averaging $1872.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$261K
- Regeneron$128K
- Mindera Corp$97K
- Amgen$77K
- Novartis$58K
- LEO Pharma AS$52K
- plus $37K from 7 others
What the payments were for
- Consulting fees$139,12811%
- Speaking & faculty fees$978,65980%
- Travel & lodging$45,0804%
- Food & beverage$60,4995%
- Education$7390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,224,105 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Taltz AutoinjectorIxekizumab | 234 | $1,557,964 |
| Skyrizi PenRisankizumab-Rzaa | 58 | $1,202,862 |
| Dupixent PenDupilumab | 298 | $1,102,301 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 105 | $766,208 |
| IlumyaTildrakizumab-Asmn | 25 | $411,522 |
| OtezlaApremilast | 85 | $396,599 |
| Cosentyx Unoready PenSecukinumab | 43 | $328,865 |
| TremfyaGuselkumab | 18 | $241,003 |
| OpzeluraRuxolitinib Phosphate | 64 | $126,001 |
| SiliqBrodalumab | 21 | $107,030 |
| VtamaTapinarof | 63 | $86,317 |
| Enbrel SureclickEtanercept | 12 | $83,191 |
| Dupixent SyringeDupilumab | 19 | $71,847 |
| SotyktuDeucravacitinib | 11 | $69,998 |
| ZoryveRoflumilast | 34 | $28,522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sun Pharmaceutical Industries Inc.Ilumya | $12,220 | $411,52225 claims |
| AmgenOtezla | $80,285 | $396,59985 claims |
| Johnson & JohnsonTremfya | $71,521 | $241,00318 claims |
| Incyte CorporationOpzelura | $61,621 | $126,00164 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCSiliq | $1,307 | $107,03021 claims |
| Dermavant Sciences, Inc.Vtama | $40,576 | $86,31763 claims |
| E.r. Squibb & Sons, L.L.C.Sotyktu | $65,973 | $69,99811 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $70,085 | $28,52234 claims |
| PfizerEucrisa | $73,357 | $14,25317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,875 dermatology providers in California.
Other dermatology in Fountain Valley
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
- Tina BhutaniSan Francisco$1.1M
- Jenny MuraseMountain View$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.